Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Registration - In-house Corporation

Boehringer Ingelheim Canada Ltd. / Mark Lewis, President and CEO

Registration Information

In-house Corporation name: Boehringer Ingelheim Canada Ltd.
Responsible Officer Name: Mark Lewis, President and CEO 
Responsible Officer Change History
Initial registration start date: 2022-05-30
Registration status: Active
Registration Number: 955680-371995

Associated Communications

Total Number of Communication Reports: 23

Monthly communication reports in the last 6 months: 3

Version 4 of 5 (2023-08-15 to 2024-04-02)

Version 4 of 5 (2023-08-15 to 2024-04-02)



Responsible Officer Name

This is the responsible officer name as provided in the most recent registration for the corporation or organization.

Name Change History:

Boehringer Ingelheim Canada Ltd./

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name From To
Boehringer Ingelheim Canada Ltd./ 2024-04-02 current
Boehringer Ingelheim Canada Ltd./ 2022-05-30 2024-04-02

Responsible Officer Change History

Boehringer Ingelheim Canada Ltd.

Responsible Officer History
Responsible Officer Name From (YYYY-MM-DD) To (YYYY-MM-DD)
Mark Lewis 2023-08-15 Current
Ruta Stauskas 2023-06-01 2023-08-15
Andrea Sambati 2022-05-30 2023-06-01

All Monthly Communication Reports for Boehringer Ingelheim Canada Ltd.

Mark Lewis, President and CEO (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-23 of 23

  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jade Mallette, Director of Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2024-04-17
    Posted date: 2024-05-15
    Communication number: 371995-603550 (amended from 371995-603473) View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Daniel MacDonald, Director General, Drugs for Rare Diseases | Strategic Policy Branch | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2024-03-22
    Posted date: 2024-05-14
    Communication number: 371995-603567 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Michelle Boudreau, Associate Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2024-03-22
    Posted date: 2024-05-14
    Communication number: 371995-603566 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Joanna Lam, Policy and Regional Affairs Advisor | Indigenous Services Canada (ISC)

    Subject Matter of the communication: Health
    Communication date: 2023-10-04
    Posted date: 2023-11-15
    Communication number: 371995-579255 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, MP | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2023-08-03
    Posted date: 2023-09-15
    Communication number: 371995-574519 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Daniel Saad, Senior Policy Advisor | Policy and Cabinet Affairs | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2023-06-29
    Posted date: 2023-08-14
    Communication number: 371995-574516 (amended from 371995-571382) View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Daniel macdonald, Director General, Drugs for Rare Diseases | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2023-05-17
    Posted date: 2023-06-15
    Communication number: 371995-570188 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Shawn Driscoll, Stakeholder Relations Advisor | House of Commons
    • Darren Hall, Office of Leader of Opposition | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2023-05-05
    Posted date: 2024-04-02
    Communication number: 371995-566301 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    • Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2023-04-24
    Posted date: 2024-04-02
    Communication number: 371995-566318 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Allison Haley, Director of Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2023-04-20
    Posted date: 2024-04-02
    Communication number: 371995-566312 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Helen Gao, Director of Policy | Indigenous Services Canada (ISC)
    • Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2023-04-13
    Posted date: 2024-04-02
    Communication number: 371995-566309 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • renee bowers, Manager and Sr Policy Analyst | Indigenous Services Canada (ISC)
    • Karen Fortin, Director | Indigenous Services Canada (ISC)

    Subject Matter of the communication: Health
    Communication date: 2023-04-11
    Posted date: 2024-04-02
    Communication number: 371995-566305 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Benoit Leduc, Manager, Socio Economic Info | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health
    Communication date: 2023-04-04
    Posted date: 2024-04-02
    Communication number: 371995-566294 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Eric Costen , Senior ADM, Industry Sector | Innovation, Science and Economic Development Canada (ISED)
    • Darryl Patterson, Director General, Life Sciences and Biomanufacturing Branch | Innovation, Science and Economic Development Canada (ISED)
    • Kasondra White, Director, Biomanufacturing Branch, Strategy Directorate | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Science and Technology
    Communication date: 2023-03-10
    Posted date: 2023-04-15
    Communication number: 371995-559405 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Health Canada (HC)
    • Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies | Health Canada (HC)
    • Daniel MacDonald, Director General, Drugs for Rare Diseases | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-12-06
    Posted date: 2023-01-13
    Communication number: 371995-553706 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies | Health Canada (HC)
    • Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-10-05
    Posted date: 2022-10-12
    Communication number: 371995-543118 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Zachary Nixon, Senior Assistant, Stakeholder Relations & Regional Affairs | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health
    Communication date: 2022-10-03
    Posted date: 2022-10-12
    Communication number: 371995-543110 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Zachary Nixon, Senior Special Assistant Stakeholder Relations and Regional Affairs | Global Affairs Canada (GAC)
    • Michelle Boudreau, Executive Director | Office of Pharmaceutical Management Strategies | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-09-13
    Posted date: 2022-09-15
    Communication number: 371995-541920 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-07-15
    Posted date: 2022-08-04
    Communication number: 371995-539058 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-07-11
    Posted date: 2022-08-04
    Communication number: 371995-539059 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Member of Parliament | House of Commons
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-07-11
    Posted date: 2022-08-04
    Communication number: 371995-539057 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Member of Parliament | House of Commons
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    • Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-28
    Communication number: 371995-536368 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ed Fast, Member of Parliament | House of Commons
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-05-30
    Posted date: 2022-06-28
    Communication number: 371995-536375 View associated registration

Monthly Communication Reports in the last 6 Months for Boehringer Ingelheim Canada Ltd.

Mark Lewis, President and CEO (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-23 of 23

  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jade Mallette, Director of Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2024-04-17
    Posted date: 2024-05-15
    Communication number: 371995-603550 (amended from 371995-603473) View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Daniel MacDonald, Director General, Drugs for Rare Diseases | Strategic Policy Branch | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2024-03-22
    Posted date: 2024-05-14
    Communication number: 371995-603567 View associated registration
  • Boehringer Ingelheim Canada Ltd.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Michelle Boudreau, Associate Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2024-03-22
    Posted date: 2024-05-14
    Communication number: 371995-603566 View associated registration

Public offices held:


Date Modified: